Homepage Top Section2

Under this agreement, McKesson will act as an authorised distributor for the immunotherapy that has received approval from the US Food and Drug Administration (FDA) to treat adults

This partnership will utilise Tempus’ de-identified multimodal database to guide the design of clinical trials. Under the multi-year agreement, Whitehawk will utilise Tempus’ real-world dataset to focus on

The FDA has also approved BeOne’s application to participate in Project Orbis, an initiative that offers a framework for concurrent submission and oncology products review among collaborating health

ADCE-D01 is an antibody-drug conjugate (ADC) designed to target the urokinase plasminogen activator receptor-associated protein (uPARAP). Preclinical data indicate that ADCE-D01 exhibits anti-tumour activity in mesenchymal tumour models,

BAT2506 is a proposed biosimilar of golimumab, developed by Bio-Thera. Golimumab is a human IgG1 monoclonal antibody that specifically targets tumour necrosis factor alpha (TNF-α), a key pro-inflammatory

The funds will be used to advance the late-stage clinical development of the company’s leading candidate, inhaled AERO-007. This nebulised LABA/LAMA combination is being developed as a potential

The oral treatment was approved for use on those who continue to experience symptoms despite receiving H1 antihistamine therapy. Rhapsido is administered in pill form twice daily and

The companies will collaborate on the development of GLIX1 as a potential treatment for both newly diagnosed and recurrent GBM. This molecule functions by enhancing TET2 activity within

The submission draws on findings from the TEMPO clinical development programme, which assessed the tolerability, efficacy, and safety of tavapadon in various populations with Parkinson’s disease. This programme